These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36732913)

  • 1. Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B.
    Huang CB; Su TH; Kao JH
    Liver Int; 2023 Apr; 43(4):947-948. PubMed ID: 36732913
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
    Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
    Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look!
    Jindal A
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1885-1886. PubMed ID: 34508869
    [No Abstract]   [Full Text] [Related]  

  • 6. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B".
    Wan YM; Wu HM; Huang SQ; Li HY; Yin HJ
    J Hepatol; 2024 May; 80(5):e229-e230. PubMed ID: 37572795
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to: "A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B'".
    van Bömmel F; Berg T
    J Hepatol; 2024 May; 80(5):e230-e231. PubMed ID: 38110010
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to the letter "Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B".
    Ohlendorf V; Maasoumy B
    Liver Int; 2023 Apr; 43(4):949. PubMed ID: 36825356
    [No Abstract]   [Full Text] [Related]  

  • 11. Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients.
    Liu YC; Jeng WJ; Chen CH
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1890-1891. PubMed ID: 34583016
    [No Abstract]   [Full Text] [Related]  

  • 12. Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B.
    Xie L; Liao G; Chen H; Xia M; Huang X; Fan R; Peng J; Zhang X; Liu H
    BMC Infect Dis; 2019 Jul; 19(1):640. PubMed ID: 31324231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IP10 and Anti-HBc can Predict Virological Relapse and HBsAg Loss in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Discontinuation.
    Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Nan Y; Zheng H; Liu J; Wei L; Feng B
    Dig Dis; 2023; 41(6):922-931. PubMed ID: 37586356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients.
    Ohlendorf V; Wübbolding M; Gineste P; Höner Zu Siederdissen C; Bremer B; Wedemeyer H; Cornberg M; Maasoumy B
    Liver Int; 2022 Dec; 42(12):2674-2682. PubMed ID: 36152268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter regarding "Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation".
    Liaw YF
    Clin Mol Hepatol; 2024 Apr; 30(2):269-271. PubMed ID: 38295765
    [No Abstract]   [Full Text] [Related]  

  • 16. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB.
    Wübbolding M; Lopez Alfonso JC; Lin CY; Binder S; Falk C; Debarry J; Gineste P; Kraft ARM; Chien RN; Maasoumy B; Wedemeyer H; Jeng WJ; Meyer Hermann M; Cornberg M; Höner Zu Siederdissen C
    Hepatol Commun; 2021 Jan; 5(1):97-111. PubMed ID: 33437904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
    Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
    Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
    Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.